MENU
+Compare
BNXTF
Stock ticker: OTC
AS OF
Aug 15 closing price
Price
$0.75
Change
-$0.02 (-2.60%)
Capitalization
90.14M

BNXTF BIONXT SOLUTIONS INC. Forecast, Technical & Fundamental Analysis

BioNxt Solutions Inc is a cannabis company focused on next-generation drug formulations and delivery systems... Show more

BNXTF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for BNXTF with price predictions
Aug 15, 2025

BNXTF's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for BNXTF turned positive on August 05, 2025. Looking at past instances where BNXTF's MACD turned positive, the stock continued to rise in of 66 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 04, 2025. You may want to consider a long position or call options on BNXTF as a result. In of 109 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

BNXTF moved above its 50-day moving average on August 04, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a +3 3-day Advance, the price is estimated to grow further. Considering data from situations where BNXTF advanced for three days, in of 135 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 96 cases where BNXTF Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNXTF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BNXTF broke above its upper Bollinger Band on August 05, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BNXTF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (16.657). P/E Ratio (0.000) is within average values for comparable stocks, (72.172). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.696). BNXTF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.031). BNXTF's P/S Ratio (5000.000) is very high in comparison to the industry average of (40.190).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNXTF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.

View a ticker or compare two or three
BNXTF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
N/A
Address
1820 Fir Street
Phone
+1 780 818-6422
Employees
6
Web
https://www.bionxt.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SNGNF3.09N/A
N/A
Singapore Telecommunications Ltd.
SULZF199.35N/A
N/A
Sulzer AG
YUBCF14.35N/A
N/A
YUBICO AB
PNPFF9.64-0.10
-1.03%
Pinetree Capital Ltd.
BLMH0.65-0.04
-5.98%
Blum Holdings Inc.

BNXTF and Stocks

Correlation & Price change

A.I.dvisor tells us that BNXTF and TAK have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BNXTF and TAK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BNXTF
1D Price
Change %
BNXTF100%
-3.09%
TAK - BNXTF
32%
Poorly correlated
+1.35%
SNOA - BNXTF
29%
Poorly correlated
+1.52%
SDZXF - BNXTF
29%
Poorly correlated
+2.12%
ALVO - BNXTF
13%
Poorly correlated
-5.31%
ESAIY - BNXTF
11%
Poorly correlated
+2.73%
More

Groups containing BNXTF

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BNXTF
1D Price
Change %
BNXTF100%
-3.09%
Pharmaceuticals
category (393 stocks)
13%
Poorly correlated
-1.04%
Pharmaceuticals: Generic
category (227 stocks)
0%
Poorly correlated
-1.78%